Centrexion Therapeutics CEO and leadership

Jeffrey B. Kindler (born May 13, 1955) is an American healthcare executive and private investor. He served as chairman and CEO of the pharmaceutical company Pfizer from 2006 to 2010. Kindler has later served as CEO of Centrexion Inc., and chairman of the GLG Institute.

Kerrie Brady brings to OcuTerra Therapeutics her experience as a successful serial biotechnology entrepreneur and strategic business leader with over 30 years of international experience across a variety of therapeutic areas. Prior to joining OcuTerra, Kerrie co-founded Centrexion Therapeutics in 2013 and served as its Chief Business Officer and Executive VP Strategy. As co-founder, she played a key role in growing the initial team from two people to a high-performing 25-person team with five clinical programs. She was instrumental in raising over $150 million in investments, led the $998 million out-licensing deal to Lilly, with over $48 million up front.

Prior to co-founding Centrexion, Kerrie was recruited in 2007 by InterWest Partners to co-found Arcion Therapeutics. As COO, she was key to raising $18 million from venture capital investors and negotiated term sheets for licensing and M&A opportunities. The acquisition of an additional asset resulted in spin-off company, Vallinex, which she led simultaneously with Arcion from 2010 to 2013. As COO at Vallinex, she was instrumental in restructuring the product, securing additional IP, and refocusing its development plan. She structured the startup’s seed funding, negotiated a Series A investment, and organized the company’s acquisition. Kerrie’s entrepreneurial path began in 2006 when she founded Traxion Therapeutics, a boutique biotech company specializing in new drugs that act on ion channels. At Traxion, she built a pipeline of novel early stage assets through in-licensing deals from Japanese pharmaceutical companies.

Kerrie’s earlier career included roles in both biotech (EntreMed, Intracel, Cooperative Research Center for Biopharmaceutical Research) and pharmaceutical organizations (Rhone Poulenc, Farmitalia Carlo Erba) with leadership positions in operations, business development, marketing, and regulatory affairs.

Kerrie holds a BPharm from the Victoria College of Pharmacy, an MBA (Award of Distinction) from the University of Melbourne and an M.S. in Biopharmaceuticals from the University of New South Wales.

Mike Ward joined Centrexion Therapeutics as CFO in 2019. He brings more than 25 years of experience, predominantly as an investment banker focused on life sciences and as both CFO and CBO of public and private life sciences companies. Prior to joining Centrexion, Mike served as CFO and CBO of Bionano Genomics, a NASDAQ-listed life sciences company. Prior to Bionano Genomics, Mike served as Executive Director of the Private Equity team of Lurie Investment Fund with a focus on life sciences investments. As an investment banker, Mike completed over 100 life sciences financings and M&A transactions (including nearly 20 IPOs) at Leerink Partners, Credit Suisse, BMO, Wasserstein and Prudential Securities. Mike has also served on the board of directors of public and private life sciences companies, including Nanosphere, CytoPherx, Aperion Biologics and Impact Health. Mike graduated summa cum laude (highest distinction) from the University of Illinois in 1993 with a Bachelor of Science in Finance with a concentration in Accounting.

James N Campbell is a President/Chief Scientific Ofce at CENTREXION THERAPEUTICS CORP, Professor at JOHNS HOPKINS UNIVERSITY, and Board Member at CENTREXION THERAPEUTICS CORP. He has worked as Board Member at Arcion Therapeutics Inc, Board Member at JOHNS HOPKINS UNIVERSITY, and Board Member at ANESIVA INC. James works or has worked as CHAIRMAN at American Pain Foundation. He studied at University of Michigan and Yale University.

Randall Stevens, M.D. joined Centrexion Therapeutics as the chief medical officer in April 2015. Randall is a board-certified internist and rheumatologist with more than 25 years of experience in pharmaceutical medicine. Prior to joining Centrexion, he served as the corporate vice president, head of inflammation and immunology clinical development for Celgene Corporation. Earlier in his career, Randall spent 11 years at F. Hoffmann La Roche where he was a global leader in inflammation and immunology clinical research. In total, Randall has played an integral role in bringing five drugs to market. Additionally, he has been a clinical professor of medicine at Robert Wood Johnson School of Medicine since 1990 and a board member for Outcome Measures Rheumatic Clinical Trails (OMERACT) since 2007. Randall has authored or co-authored more than 40 peer-reviewed publications. He holds a B.A. in chemistry and Spanish, and a M.D. from Case Western Reserve University School of Medicine.

Andrew Partridge serves as executive vice president and chief commercial officer. Mr. Partridge has more than 20 years of global pharmaceutical sales and marketing experience leading more than 20 commercial launches across multiple indications, including oncology, hematology and rare diseases.

Prior to joining Turning Point Therapeutics, Mr. Partridge was both chief operating officer and chief commercial officer of Centrexion Therapeutics, a privately held biotech. He was previously with Vertex Pharmaceuticals for 5 years, most recently as senior vice president and head of North American commercial operations where he built the team to successfully launch multiple cystic fibrosis therapies and new indications. Mr. Partridge had overall responsibility at Vertex across the U.S. and Canada for marketing, sales, market access and patient services and led the cross-functional North American leadership team that included medical affairs, finance, legal and human resources. In the preceding 20 years, he served in sales and marketing roles of increasing responsibility with Schering-Plough, Roche and Amgen. At Amgen, he held senior marketing and sales roles for oncology and hematology therapeutics, including strategic planning and operations of the $5 billion oncology business unit, and therapeutic area head for oncology in global strategic marketing. His global experience also includes marketing and sales management roles based in the U.K. at Roche and Schering-Plough focused on oncology and hematology. He earned a Higher National Diploma in Medical Laboratory Sciences from Birmingham City University in the U.K.

Kerrie Brady brings to OcuTerra Therapeutics her experience as a successful serial biotechnology entrepreneur and strategic business leader with over 30 years of international experience across a variety of therapeutic areas. Prior to joining OcuTerra, Kerrie co-founded Centrexion Therapeutics in 2013 and served as its Chief Business Officer and Executive VP Strategy. As co-founder, she played a key role in growing the initial team from two people to a high-performing 25-person team with five clinical programs. She was instrumental in raising over $150 million in investments, led the $998 million out-licensing deal to Lilly, with over $48 million up front.

Prior to co-founding Centrexion, Kerrie was recruited in 2007 by InterWest Partners to co-found Arcion Therapeutics. As COO, she was key to raising $18 million from venture capital investors and negotiated term sheets for licensing and M&A opportunities. The acquisition of an additional asset resulted in spin-off company, Vallinex, which she led simultaneously with Arcion from 2010 to 2013. As COO at Vallinex, she was instrumental in restructuring the product, securing additional IP, and refocusing its development plan. She structured the startup’s seed funding, negotiated a Series A investment, and organized the company’s acquisition. Kerrie’s entrepreneurial path began in 2006 when she founded Traxion Therapeutics, a boutique biotech company specializing in new drugs that act on ion channels. At Traxion, she built a pipeline of novel early stage assets through in-licensing deals from Japanese pharmaceutical companies.

Kerrie’s earlier career included roles in both biotech (EntreMed, Intracel, Cooperative Research Center for Biopharmaceutical Research) and pharmaceutical organizations (Rhone Poulenc, Farmitalia Carlo Erba) with leadership positions in operations, business development, marketing, and regulatory affairs.

Kerrie holds a BPharm from the Victoria College of Pharmacy, an MBA (Award of Distinction) from the University of Melbourne and an M.S. in Biopharmaceuticals from the University of New South Wales.

Jeffrey B. Kindler (born May 13, 1955) is an American healthcare executive and private investor. He served as chairman and CEO of the pharmaceutical company Pfizer from 2006 to 2010. Kindler has later served as CEO of Centrexion Inc., and chairman of the GLG Institute.